Duloxetine

Generic Name
Duloxetine
Brand Names
Cymbalta, Drizalma, Irenka, Yentreve, Duloxetine Zentiva, Duloxetine Mylan, Duloxetine Lilly
Drug Type
Small Molecule
Chemical Formula
C18H19NOS
CAS Number
116539-59-4
Unique Ingredient Identifier
O5TNM5N07U
Background

Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor. It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval for a variety of indications including the tre...

Indication

Indicated for:

1) Management of Major Depressive Disorder.

2) Management of Generalized Anxiety Disorder.

3) Management of diabetic peripheral neuropathy.

4) Management of fibromyalgia.

5) Management of chronic musculoskeletal pain.

6) Management of osteoarthritis of the knee in adults.

7) Management of chronic lower back pain in adults.
...

Associated Conditions
Chronic Lower Back Pain (CLBP), Chronic Musculoskeletal Pain, Diabetic Peripheral Neuropathic Pain (DPN), Fibromyalgia, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Osteoarthritis of the Knee, Stress Urinary Incontinence (SUI)
Associated Therapies
-
Clinical Trials
Related News

Prospective RCT on Post Prostatectomy Urine Leak

First Posted Date
2015-02-20
Last Posted Date
2016-09-13
Lead Sponsor
Institut Mutualiste Montsouris
Target Recruit Count
240
Registration Number
NCT02367404
Locations
🇫🇷

Institut Mutualiste montsouris, Paris, France

Effect of Preoperative Duloxetine on Quality of Recovery After Outpatient Laparoscopic Surgery

First Posted Date
2015-01-30
Last Posted Date
2018-08-21
Lead Sponsor
Northwestern University
Registration Number
NCT02351440
Locations
🇺🇸

Prentice Womens Hospital, Chicago, Illinois, United States

An Extension Study of Duloxetine in Osteoarthritis and Knee Pain (Extension of F1J-JE-HMGX, NCT02248480)

Phase 3
Completed
Conditions
Osteoarthritis of the Knee
Interventions
Drug: Duloxetine
First Posted Date
2015-01-09
Last Posted Date
2019-09-18
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
93
Registration Number
NCT02335346
Locations
🇯🇵

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kobe, Japan

Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury

First Posted Date
2014-12-19
Last Posted Date
2016-03-14
Lead Sponsor
Canadian Network for Observational Drug Effect Studies, CNODES
Target Recruit Count
3255526
Registration Number
NCT02320240
Locations
🇨🇦

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada

Does Duloxetine Reduce Chronic Pain After Total Knee Arthroplasty?

First Posted Date
2014-12-04
Last Posted Date
2016-02-19
Lead Sponsor
Hanyang University Seoul Hospital
Target Recruit Count
168
Registration Number
NCT02307305
Locations
🇰🇷

Department of Orthopaedic Surgery, Hanyang University, College of Medicine, Seoul, Korea, Republic of

Bioavailability Study of Duloxetine Delayed-Release Capsules 60 mg Under Fasting Condition

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Cymbalta®
Drug: Duloxetine
First Posted Date
2014-11-14
Last Posted Date
2014-11-14
Lead Sponsor
Dr. Reddy's Laboratories Limited
Target Recruit Count
76
Registration Number
NCT02291367
Locations
🇮🇳

BA Research India Ltd, Ahmedabad, Gujrat, India

Bioavailability Study of Duloxetine Delayed-Relase Capsules 60 mg Under Fed Condition

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Cymbalta®
Drug: Duloxetine
First Posted Date
2014-11-14
Last Posted Date
2014-11-14
Lead Sponsor
Dr. Reddy's Laboratories Limited
Target Recruit Count
76
Registration Number
NCT02291341
Locations
🇮🇳

BA Research India Ltd, Ahmedabad, Gujrat, India

Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations

First Posted Date
2014-10-09
Last Posted Date
2018-07-06
Lead Sponsor
University of Kansas Medical Center
Target Recruit Count
402
Registration Number
NCT02260388
Locations
🇺🇸

Cedars-Sinai Medical Center, Los Angeles, California, United States

🇺🇸

University of Miami Miller School of Medicine, Miami, Florida, United States

🇺🇸

Indiana University, Indianapolis, Indiana, United States

and more 43 locations

A Study of Duloxetine (LY248686) in Participants With Chronic Osteoarthritis and Knee Pain in Japan

Phase 3
Completed
Conditions
Osteoarthritis of the Knee
Interventions
Drug: Duloxetine
Drug: Placebo
First Posted Date
2014-09-25
Last Posted Date
2019-09-26
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
354
Registration Number
NCT02248480
Locations
🇯🇵

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyogo, Japan

Study to Evaluate the Efficacy of Duloxetine in Outpatients With Major Depressive Disorder and Pain

Phase 3
Completed
Conditions
Depressive Disorder, Major
Interventions
Drug: Placebo
Drug: Duloxetine
First Posted Date
2014-09-05
Last Posted Date
2014-09-05
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
327
Registration Number
NCT02232555
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy